Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

d be available by the middle of this year. Once we have reviewed the data from this study, we will decide on our future development plans with microplasmin for the treatment of acute stroke."

About Stroke

Stroke is a cardiovascular disease affecting the blood vessels of the brain. Stroke is caused by a blockage of the blood vessels of the brain, depriving the brain of oxygen, and can result in severe neurological damage and death. After heart diseases and cancer, stroke is the third most frequent cause of death and the leading cause of disability in the Western world. It is estimated that over two million people suffer a stroke annually. Mortality is high with 20% of patients dying, while the majority of the remainder are left permanently disabled.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-loo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014  Armetheon, ... on developing novel mid- to late-stage cardiovascular drug ... million in its first round of financing. The ... Investments and Hercules Bioventures with participation from investors ... and pharmaceutical executive, Dr. Larry Hsu , ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge in ... 2014 symposium. Marking its 46th year, the annual ... 14-17 September. The event is sponsored by SPIE, ... The premier conference for basic and applied issues which ... will engage researchers and engineers from numerous industries and ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... the Risks of DVT to Mark U.S. House of ... Coalition to Prevent DVT today announced the launch of ... deep-vein thrombosis (DVT) and to encourage dialogue between healthcare ... A customized recreational vehicle will visit hospitals and ...
... Christine Lawless, MD, has accepted the position as Medical ... medical education (CME), beginning March 2, 2009. Recognized as ... cardiology, Dr. Lawless recently completed her clinical tenure at ... she was Associate Professor of Internal Medicine and Co-Director ...
... March 10 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced that Kumar Kastury, Ph.D., ... will present data on the company,s SmartChip(TM) Real-Time ... Anniversary Quantitative PCR Conference. The conference will ...
Cached Biology Technology:The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 2The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 3The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 4The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 5Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institute's Quantitative PCR Conference 2WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institute's Quantitative PCR Conference 3WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institute's Quantitative PCR Conference 4
(Date:8/28/2014)... method for measuring and imaging how quickly blood flows ... understand how drug abuse affects the brain, which may ... lead to better treatment options for recovering drug addicts. ... from Stony Brook University in New York, USA and ... in The Optical Society,s (OSA) open-access journal ...
(Date:8/28/2014)... of new roads will be built worldwide by 2050. ... wildernesses, where they bring an influx of destructive loggers, ... study has created a ,global roadmap, for prioritising road ... competing demands of development and environmental protection. , The ... that natural importance of ecosystems and a ,road-benefits, layer ...
(Date:8/28/2014)... pose a significant health risk to people with asthma according ... Allergy and Clinical Immunology . , By critically reviewing the ... has found that the presence of several types of mould ... as increasing the likelihood of developing the condition. , The ... of Exeter Medical School and is the first time all ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Indoor mold poses health risk to asthma sufferers 2
... nearby mosquito is the sound of love, scientists have known ... males and females flap their wings and change their tune ... have discovered that male and female mosquitoes (Aedes aegypti), which ... acoustically with each other when the two are within earshot ...
... evolutionary history of diatoms -- abundant oceanic plankton that remove ... year -- needs to be rewritten, according to a new ... in species numbers, diatoms abruptly declined about 33 million years ... The study is published in the Jan. 8 issue of ...
... available in German . , The ... proton. If a neutron is added, the hydrogen becomes ... of hydrogen atoms are chemically identical. However, there can ... that contain deuterium in place of hydrogen, is toxic ...
Cached Biology News:Mosquitoes create harmonic love song before mating, study finds 2Decline of carbon-dioxide-gobbling plankton coincided with ancient global cooling 2Heavy pyridine crystallizes differently 2
... VersArray ChipReader systems are highly sensitive ... of microarrays. These are advanced scanners that ... response and background level, and optimizing the ... the top end of the range for ...
... assays on four slides. The new ArraySlide ... 96 (6mm x 7mm) individual printing surfaces ... screening analysis studies. Unlike other systems, this ... the presence of contaminating adhesives. The chamber ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
... are rigid macroporous hydrophilic media. The rigid ... moderate pressures, while the macroporous beads enhance ... matrix reduces nonspecific binding. Macro-Prep High Q ... with very high flow rates and resolution. ...
Biology Products: